Researchers at Lund University in Sweden have identified a protein in the brain's immune cells that appears to actively shape the damaging plaques characteristic of Alzheimer's disease, according to a study published in PNAS.

The protein, galectin-3, is produced by microglia — the brain's resident immune cells. The Lund team found that it binds strongly to beta-amyloid (Aβ), the protein fragment that clumps into plaques in Alzheimer's patients. Galectin-3 acts in two places at once: on the plaque itself, where it alters the shape of growing amyloid fibres, and inside the microglia's lysosomes, where it influences how the cell processes the amyloid it has engulfed.

"No one has previously shown what galectin-3 does to the plaque itself," said Lluís Camprubí-Ferrer, a postdoctoral researcher at Lund and one of the study's lead authors, in a university press release. "We have observed that the protein binds to long protein strands known as amyloid fibrils, blocking one of the steps by which they multiply and altering their shape. In cell experiments, the fibrils reshaped by galectin-3 went on to damage nerve cells."

The study, conducted in collaboration with the University of Seville and the Instituto de Biomedicina de Sevilla (IBiS) in Spain, used both mouse models and human tissue samples. When the researchers removed galectin-3 in mice with an Alzheimer's-like condition, the plaques became smaller and more tightly packed. The surrounding nerve endings showed significantly less damage, and the microglia shifted from an aggressive, inflammatory state to a protective one.

"When we inactivated galectin-3, microglia transitioned from their harmful state to a state rich in the protective receptor TREM2, a protein that we know plays an important role in the brain's immune defence and in the risk of Alzheimer's disease," Camprubí-Ferrer said.

The animal experiments demonstrated a clear cause-and-effect relationship, according to the researchers. The human tissue work, based on samples from nine individuals, showed a strong correlation — though the team cautioned that only a clinical trial can determine whether blocking galectin-3 actually helps patients.

"This is important because current Alzheimer's drugs target amyloid without helping to reduce inflammation in the brain," Camprubí-Ferrer noted. "And galectin-3 is a protein that drugs can actually bind to."

Tomas Deierborg, professor and leader of the Experimental Neuroinflammation research group at Lund, said the timing is right for this line of investigation. "Drugs containing antibodies that break down amyloid have reached patients, but their modest effect has drawn attention to the brain's immune response. That is where we can now fill in the gaps," he said in the release.

Deierborg noted that just weeks ago, US regulators approved a Phase 2 clinical trial for an antibody that blocks galectin-3 — a development he called "encouraging" and a demonstration of the clinical potential of the research.

The findings are particularly relevant for students and researchers in neuroscience, medicine, and biomedical science. Understanding how galectin-3 links immune function to amyloid aggregation could shape future research directions and therapeutic strategies for Alzheimer's, a disease that affects millions worldwide and remains a major focus of academic and pharmaceutical research.

For students considering careers in neurodegenerative disease research, the study highlights the growing importance of the brain's immune response — an area that current treatments do not address. The rapid translation from basic discovery to clinical trial also underscores how university research can directly influence drug development.

The study was funded by the Strategic Research Area MultiPark at Lund University, the Swedish Research Council, the Alzheimer Foundation, and several other foundations.